{"id":7633,"date":"2023-08-19T09:31:36","date_gmt":"2023-08-19T09:31:36","guid":{"rendered":"http:\/\/d1s07skqdwll4z.cloudfront.net\/mrcc-tool\/reference-list\/"},"modified":"2024-03-28T17:27:12","modified_gmt":"2024-03-28T17:27:12","slug":"reference-list","status":"publish","type":"page","link":"https:\/\/d1s07skqdwll4z.cloudfront.net\/no\/mrcc-tool\/reference-list\/","title":{"rendered":"Reference list"},"content":{"rendered":"<p><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-padding-top:-60px;--awb-background-color:var(--awb-color3);--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:1.92%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:1.92%;--awb-width-medium:100%;--awb-order-medium:0;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-search-element fusion-search-element-1 fusion-search-form-clean\" style=\"--awb-border-radius:7px;--awb-text-color:var(--awb-color8);--awb-border-color:var(--awb-color8);--awb-bg-color:var(--awb-color3);\">\t\t<form role=\"search\" class=\"searchform fusion-search-form  fusion-live-search fusion-search-form-clean\" method=\"get\" action=\"https:\/\/d1s07skqdwll4z.cloudfront.net\/no\/\">\n\t\t\t<div class=\"fusion-search-form-content\">\n\n\t\t\t\t\n\t\t\t\t<div class=\"fusion-search-field search-field\">\n\t\t\t\t\t<label><span class=\"screen-reader-text\">Search for:<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<input type=\"search\" class=\"s fusion-live-search-input\" name=\"s\" id=\"fusion-live-search-input-0\" autocomplete=\"off\" placeholder=\"Search...\" required aria-required=\"true\" aria-label=\"Search...\"\/>\n\t\t\t\t\t\t\t\t\t\t\t<\/label>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"fusion-search-button search-button\">\n\t\t\t\t\t<input type=\"submit\" class=\"fusion-search-submit searchsubmit\" aria-label=\"Search\" value=\"&#xf002;\" \/>\n\t\t\t\t\t\t\t\t\t\t<div class=\"fusion-slider-loading\"><\/div>\n\t\t\t\t\t\t\t\t\t<\/div>\n\n\t\t\t\t<input type=\"hidden\" name=\"post_type[]\" value=\"any\" \/><input type=\"hidden\" name=\"search_limit_to_post_titles\" value=\"0\" \/><input type=\"hidden\" name=\"live_min_character\" value=\"4\" \/><input type=\"hidden\" name=\"live_posts_per_page\" value=\"100\" \/><input type=\"hidden\" name=\"live_search_display_featured_image\" value=\"1\" \/><input type=\"hidden\" name=\"live_search_display_post_type\" value=\"1\" \/><input type=\"hidden\" name=\"fs\" value=\"1\" \/>\n\t\t\t<\/div>\n\n\n\t\t\t\t\t\t\t<div class=\"fusion-search-results-wrapper\"><div class=\"fusion-search-results\"><\/div><\/div>\n\t\t\t\n\t\t<\/form>\n\t\t<\/div><\/div><\/div><\/div><\/div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-2 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-margin-top:4px;--awb-background-color:var(--awb-color3);--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-1 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:1.92%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:1.92%;--awb-width-medium:100%;--awb-order-medium:0;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-title title fusion-title-1 fusion-title-center fusion-title-text fusion-title-size-five\" style=\"--awb-text-color:#c1c1c1;--awb-sep-color:#e2e2e2;\"><div class=\"title-sep-container title-sep-container-left\"><div class=\"title-sep sep-single sep-solid\" style=\"border-color:#e2e2e2;\"><\/div><\/div><span class=\"awb-title-spacer\"><\/span><h5 class=\"fusion-title-heading title-heading-center\" style=\"margin:0;\">Reference list<\/h5><span class=\"awb-title-spacer\"><\/span><div class=\"title-sep-container title-sep-container-right\"><div class=\"title-sep sep-single sep-solid\" style=\"border-color:#e2e2e2;\"><\/div><\/div><\/div><div class=\"fusion-title title fusion-title-2 fusion-title-center fusion-title-text fusion-title-size-five\" style=\"--awb-text-color:#c1c1c1;--awb-sep-color:#e2e2e2;\"><div class=\"title-sep-container title-sep-container-left\"><div class=\"title-sep sep-single sep-solid\" style=\"border-color:#e2e2e2;\"><\/div><\/div><span class=\"awb-title-spacer\"><\/span><h5 class=\"fusion-title-heading title-heading-center\" style=\"margin:0;\">Introduction<\/h5><span class=\"awb-title-spacer\"><\/span><div class=\"title-sep-container title-sep-container-right\"><div class=\"title-sep sep-single sep-solid\" style=\"border-color:#e2e2e2;\"><\/div><\/div><\/div><div class=\"fusion-title title fusion-title-3 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Reference 1.1<\/h4><\/div><div class=\"fusion-text fusion-text-1\"><ol class=\"reference\">\n<li class=\"reference\"><em>Azeem K, Kollarova H, Horakova D, Magnuskova S, Janout V. Genetic syndromes associated with renal cell carcinoma: a review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2011;155(3):231-238.<\/em><\/li>\n<li class=\"reference\"><em>Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practise Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 0: 1\u201315, 2019<\/em><\/li>\n<li class=\"reference\"><em>Nordcan database accessed May 2019<\/em><\/li>\n<li class=\"reference\"><em>RADS, \u201cBaggrundsnotat for medicinsk behandling af metastaserende nyrekr\u00e6ft,\u201d 2016<\/em><\/li>\n<li class=\"reference\"><em>WCRJ 2018, 5 (8)<\/em><\/li>\n<li class=\"reference\"><em>Ferlay et al, EJCA 103(2018) 356\u2013387<\/em><\/li>\n<li class=\"reference\"><em>Ljungberg B, Bensalah K, Bex A, et al. EAU guidelines on renal cell carcinoma: 2016 update. European Association of Urology. https:\/\/uroweb.org\/guideline\/renal-cell-carcinoma\/. Accessed 25 June 2016. .<\/em><\/li>\n<li class=\"reference\"><em>Epidemiology and Risk Factors for Kidney Cancer, JClinOncol 36 1018<\/em><\/li>\n<\/ol>\n<\/div><div class=\"fusion-title title fusion-title-4 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Reference 1.2<\/h4><\/div><div class=\"fusion-text fusion-text-2\"><ol>\n<li><em>Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practise Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 0: 1\u201315, 2019<\/em><\/li>\n<li><em>Linehan WM, Rini BI, Yang JC. Cancer of the kidney. I: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg\u2019s Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2011:1161\u20131182.<\/em><\/li>\n<li><em>Zhou M, Hattab EM, Eble JN, Cheng L. Neoplasms of the kidney. I: Zhou M, Galluzi-Magi C, eds. Genitourinary Pathology. 2nd ed. Philadelphia, PA: Elsevier Saunders; 2015:306\u2013377.<\/em><\/li>\n<li><em>Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010;7(5):245\u2013257.<\/em><\/li>\n<li><em>New 5 K\u00fcmmerlin IPED, Laguna MP, de la Rosette JJMCH, Bossuyt PMM. Epidemiology of renal cell carcinoma. I: de la Rosette JJMCH, Sternberg CN, van Poppel HPA, eds. Renal Cell Cancer: Diagnosis and Therapy. London: Springer-Verlag; 2008:1-8.<\/em><\/li>\n<li><em>Kim I, Ha J, Lee JH, et al. The relationship between the occupational exposure of trichloroethylene and kidney cancer. Ann Occup Environ Med. 2014;26:1-9.<\/em><\/li>\n<li><em>Epidemiology and Risk Factors for Kidney Cancer, JClinOncol 36 1018<\/em><\/li>\n<\/ol>\n<\/div><div class=\"fusion-title title fusion-title-5 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Reference 1.3<\/h4><\/div><div class=\"fusion-text fusion-text-3\"><ol>\n<li><em>DaRenCa guidelines<\/em><\/li>\n<li><em>ESMO, The 2016 WHO classification of tumours of the urinary system and male genital organs \u2013 Part A: renal, penile and testicular tumours. Moch et al. Eur Urol 2016 (70)<\/em><\/li>\n<li><em>Deng FM, Melamed J. Histologic variants of renal cell carcinoma: does tumor type influence outcome? ol Clin North Am. 2012;39(2):119-132, v<\/em><\/li>\n<li><em>Delacroix Jr SE, Wood CG, Jonasch E. Renal neoplasia. I: Taal MW, Chertow GM, Marsden PA, Skorecki K, Yu ASL, Brenner BM, eds. Brenner &amp; Recter\u2019s The Kidney. 9th ed. Philadelphia, PA: Elsevier Saunders; 2012:1508-1535<\/em><\/li>\n<li><em>Linehan WM, Rini BI, Yang JC. Cancer of the kidney. I: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg\u2019s Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2011:1161-1182<\/em><\/li>\n<li><em>Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373(19):1814-1823<\/em><\/li>\n<li><em>Zhou M, Hattab EM, Eble JN, Cheng L. Neoplasms of the kidney. I: Zhou M, Galluzi-Magi C, eds. Genitourinary Pathology. 2nd ed. Philadelphia, PA: Elsevier Saunders; 2015:306-377<\/em><\/li>\n<li><em>Lenehan &amp; Zbar Cancer cell 2004<\/em><\/li>\n<\/ol>\n<\/div><div class=\"fusion-title title fusion-title-6 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Reference 1.4<\/h4><\/div><div class=\"fusion-text fusion-text-4\"><ol>\n<li><em>DaRenCa \u00e5rsrapport, http:\/\/ducg.dk\/fileadmin\/www.ducg.dk\/Nyrecancer\/DaRenCa_AArsrapport_2017-18.pdf<\/em><\/li>\n<li><em>Patard J, Culine S, Ravaud A. Metastatic renal cell carcinoma. I: Lyden D, Welch DR, Psaila B, eds. Cancer Metastasis: Biologic Basis and Therapeutics. New York, NY: Cambridge University Press; 2011:387\u2013394<\/em><\/li>\n<li><em>Otaibi MA, Tanguay S. Locally advanced renal cell carcinoma. Can Urol Assoc J. 2007;1(2 Suppl):S55-S61<\/em><\/li>\n<\/ol>\n<\/div><div class=\"fusion-title title fusion-title-7 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Reference 1.5<\/h4><\/div><div class=\"fusion-text fusion-text-5\"><ol class=\"reference\">\n<li><em>Kidney cancer (adult) \u2013 renal cell carcinoma. American Cancer Society. http:\/\/www.cancer.org\/acs\/groups\/cid\/documents\/webcontent\/003107-pdf.pdf. Accessed 14 June 2016.<\/em><\/li>\n<li><em>Delacroix Jr SE, Wood CG, Jonasch E. Renal neoplasia. I: Taal MW, Chertow GM, Marsden PA, Skorecki K, Yu ASL, Brenner BM, eds. Brenner &amp; Recter\u2019s The Kidney. 9th ed. Philadelphia, PA: Elsevier Saunders; 2012:1508\u20131535.<\/em><\/li>\n<li><em>Deng FM, Melamed J. Histologic variants of renal cell carcinoma: does tumour type influence outcome? Urol Clin North Am. 2012;39(2):119-132, v.<\/em><\/li>\n<li><em>Kidney cancer stages. Cancer.Net. http:\/\/www.cancer.net\/cancer-types\/kidney-cancer\/stages. Accessed 20 June 2016.<\/em><\/li>\n<\/ol>\n<\/div><div class=\"fusion-title title fusion-title-8 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Reference 1.6<\/h4><\/div><div class=\"fusion-text fusion-text-6\"><ol class=\"reference\">\n<li><em>Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. 2009;373(9669):1119\u20131132.<\/em><\/li>\n<li><em>Linehan WM, Bratslavsky G, Pinto PA, et al. Molecular diagnosis and therapy of kidney cancer. Annu Rev Med. 2010;61:329-343.<\/em><\/li>\n<li><em>Semenza GL. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J Clin Invest. 2013;123(9):3664-3671.<\/em><\/li>\n<li><em>Banumathy G, Cairns P. Signaling pathways in renal cell carcinoma. Cancer Biol Ther. 2010;10(7):658\u2013664.<\/em><\/li>\n<li><em>Pili R, Kauffman E, Rodriguez R. Cancer of the kidney. I: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff\u2019s Clinical Oncology. 5th ed. Philadelphia, PA: Elsevier Saunders; 2014:1416\u20131444.<\/em><\/li>\n<li><em>Choueiri TK, et al. N Engl J Med 2015;373:1814\u201323<\/em><\/li>\n<li><em>Gibney GT, et al. Ann Oncol 2013;24:343\u20139<\/em><\/li>\n<li><em>Rankin EB, et al. PNAS 2014;111:13373\u20138<\/em><\/li>\n<li><em>Zhou L, et al. Oncogene 2016;35:2687\u201397<\/em><\/li>\n<\/ol>\n<\/div><\/div><\/div><\/div><\/div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-3 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-margin-top:4px;--awb-background-color:var(--awb-color3);--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-2 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:1.92%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:1.92%;--awb-width-medium:100%;--awb-order-medium:0;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-title title fusion-title-9 fusion-title-center fusion-title-text fusion-title-size-five\" style=\"--awb-text-color:#c1c1c1;--awb-sep-color:#e2e2e2;\"><div class=\"title-sep-container title-sep-container-left\"><div class=\"title-sep sep-single sep-solid\" style=\"border-color:#e2e2e2;\"><\/div><\/div><span class=\"awb-title-spacer\"><\/span><h5 class=\"fusion-title-heading title-heading-center\" style=\"margin:0;\">Symptoms and diagnosis<\/h5><span class=\"awb-title-spacer\"><\/span><div class=\"title-sep-container title-sep-container-right\"><div class=\"title-sep sep-single sep-solid\" style=\"border-color:#e2e2e2;\"><\/div><\/div><\/div><div class=\"fusion-title title fusion-title-10 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Reference 2.1<\/h4><\/div><div class=\"fusion-text fusion-text-7\"><ol class=\"reference\">\n<li><em>NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) \u2013 Kidney Cancer. NCCN.2018<\/em><\/li>\n<li><em>ESMO guidelines 2019<\/em><\/li>\n<li><em>EAU guidelines 2017<\/em><\/li>\n<li><em>DaRenCa guidelines<\/em><\/li>\n<\/ol>\n<\/div><div class=\"fusion-title title fusion-title-11 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Reference 2.2<\/h4><\/div><div class=\"fusion-text fusion-text-8\"><ol class=\"reference\">\n<li>\n<p class=\"reference\"><em>ESMO, DaRenCa and NCCN guidelines<\/em><\/p>\n<\/li>\n<\/ol>\n<\/div><div class=\"fusion-title title fusion-title-12 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Reference 2.3<\/h4><\/div><div class=\"fusion-text fusion-text-9\"><ol class=\"reference\">\n<li>\n<p class=\"reference\"><em>ESMO, EAU, DaRenCa and NCCN guidelines<\/em><\/p>\n<\/li>\n<\/ol>\n<\/div><div class=\"fusion-title title fusion-title-13 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Reference 2.4<\/h4><\/div><div class=\"fusion-text fusion-text-10\"><ol>\n<li><em>Prognostication in Kidney Cancer: Recent Advances and Future Directions Jeffrey Graham, Shaan Dudani, and Daniel Y.C. Heng<\/em><\/li>\n<li><em>ESMO guidelines<\/em><\/li>\n<li><em>Motzer RJ, Bacik J, Murphy BA, et al:Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289-296, 2002<\/em><\/li>\n<li><em>Heng DYC, Xie W, Regan MM, et al: Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicentre study. J Clin Oncol 27: 5794\u20135799, 2009<\/em><\/li>\n<li><em>Heng DYC, Xie W, Regan MM, et al: External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: A population-based study. Lancet Oncol 14:141\u2013148, 2013<\/em><\/li>\n<li><em>Kroeger N, Xie W, Lee JL, et al: Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: Characterisation of survival outcome and application of the International mRCC Database Consortium criteria. Cancer 119: 2999\u20133006, 2013<\/em><\/li>\n<li><em>Ko JJ, Xie W, Kroeger N, et al: The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: A population-based study. Lancet Oncol 16:293\u2013300, 2015<\/em><\/li>\n<li><em>Wells JC, Stukalin I, Norton C, et al: Third-line targeted therapy in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 71: 204\u2013209, 2017<\/em><\/li>\n<li><em>Yip S, Wells C, Brandao Moreira R, et al: Real world experience of immuno-oncology agents in metastatic renal cell carcinoma: Results from the IMDC. J Clin Oncol 35:492, 2017 (6_suppl)<\/em><\/li>\n<\/ol>\n<\/div><div class=\"fusion-title title fusion-title-14 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Reference 2.5<\/h4><\/div><div class=\"fusion-text fusion-text-11\"><ol>\n<li><em>Prognostication in Kidney Cancer: Recent Advances and Future Directions Jeffrey Graham, Shaan Dudani, and Daniel Y.C. Heng<\/em><\/li>\n<li><em>EAU guidelines on renal cell carcinoma:<\/em><\/li>\n<li><em>B. Ljungberg (Chair), L. Albiges, K. Bensalah, A. Bex (Vice-chair), R.H. Giles (Patient Advocate), M. Hora, M.A. Kuczyk, T. Lam, L. Marconi, A.S. Merseburger, T. Powles,M. Staehler, A. Volpe Guidelines Associates: S. Dabestani, S. Fern\u00e1ndez-Pello Montes, F. Hofmann, R. Tahbaz<\/em><\/li>\n<li><em>Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020<\/em><\/li>\n<li><em>B. Escudier1, C. Porta2, M. Schmidinger3, N. Rioux-Leclercq4, A. Bex5, V. Khoo6,7, V. Gruenvald8 &amp; A. Horwich9 on behalf of the ESMO Guidelines Committee*<\/em><\/li>\n<\/ol>\n<\/div><\/div><\/div><\/div><\/div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-4 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-margin-top:4px;--awb-background-color:var(--awb-color3);--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-3 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:1.92%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:1.92%;--awb-width-medium:100%;--awb-order-medium:0;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-title title fusion-title-15 fusion-title-center fusion-title-text fusion-title-size-five\" style=\"--awb-text-color:#c1c1c1;--awb-sep-color:#e2e2e2;\"><div class=\"title-sep-container title-sep-container-left\"><div class=\"title-sep sep-single sep-solid\" style=\"border-color:#e2e2e2;\"><\/div><\/div><span class=\"awb-title-spacer\"><\/span><h5 class=\"fusion-title-heading title-heading-center\" style=\"margin:0;\">Management of mRCC<\/h5><span class=\"awb-title-spacer\"><\/span><div class=\"title-sep-container title-sep-container-right\"><div class=\"title-sep sep-single sep-solid\" style=\"border-color:#e2e2e2;\"><\/div><\/div><\/div><div class=\"fusion-title title fusion-title-16 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Reference 3.1<\/h4><\/div><div class=\"fusion-text fusion-text-12\"><ol>\n<li><em>ESMO guildeline, DaRenCa guideline EUA guideline<\/em><\/li>\n<li><em>Medicinr\u00e5det, https:\/\/medicinraadet.dk\/media\/eqenldkj\/medicinr%C3%A5dets_behandlingsvejledning_vedr-_l%C3%A6gemidler_til_metastatisk_nyrekr%C3%A6ft-vers-_1-0_adlegacy.pdf<\/em><\/li>\n<\/ol>\n<\/div><div class=\"fusion-title title fusion-title-17 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Reference 3.2<\/h4><\/div><div class=\"fusion-text fusion-text-13\"><ol>\n<li><em>The Cancer Department, Herlev Hospital<\/em><\/li>\n<\/ol>\n<\/div><div class=\"fusion-title title fusion-title-18 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Reference 3.3<\/h4><\/div><div class=\"fusion-text fusion-text-14\"><ol>\n<li><em>The Cancer Department Herlev Hospital<\/em><\/li>\n<\/ol>\n<\/div><div class=\"fusion-title title fusion-title-19 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Reference 3.4<\/h4><\/div><div class=\"fusion-text fusion-text-15\"><ol>\n<li><em>Eisenhauer EA et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). EJC 2019)<\/em><\/li>\n<li><em>Seymour et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics, Lancet Oncol 2017.<\/em><\/li>\n<\/ol>\n<\/div><div class=\"fusion-title title fusion-title-20 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Reference 3.5<\/h4><\/div><div class=\"fusion-text fusion-text-16\"><ol>\n<li><em>Symptomkontrol i palliativ medicin 5. udg., Steen Andersen et al, FADL\u2019s forlag, KBH 2012<\/em><\/li>\n<li><em>SKA guidelines<\/em><\/li>\n<\/ol>\n<\/div><div class=\"fusion-title title fusion-title-21 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Reference 3.6<\/h4><\/div><div class=\"fusion-text fusion-text-17\"><ol>\n<li><em>Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., Carbone, P.P.: Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982<\/em><\/li>\n<li><em>Karnofsky DA, Burchenal JH. In: Evaluation of chemotherapeutic agents. MacLeod CM, editor. New York: Columbia University Press; 1949. The clinical evaluation of chemotherapeutic agents in cancer; pp. 191\u2013205<\/em><\/li>\n<\/ol>\n<\/div><\/div><\/div><\/div><\/div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-5 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-margin-top:4px;--awb-background-color:var(--awb-color3);--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-4 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:1.92%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:1.92%;--awb-width-medium:100%;--awb-order-medium:0;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-title title fusion-title-22 fusion-title-center fusion-title-text fusion-title-size-five\" style=\"--awb-text-color:#c1c1c1;--awb-sep-color:#e2e2e2;\"><div class=\"title-sep-container title-sep-container-left\"><div class=\"title-sep sep-single sep-solid\" style=\"border-color:#e2e2e2;\"><\/div><\/div><span class=\"awb-title-spacer\"><\/span><h5 class=\"fusion-title-heading title-heading-center\" style=\"margin:0;\">Treatment<\/h5><span class=\"awb-title-spacer\"><\/span><div class=\"title-sep-container title-sep-container-right\"><div class=\"title-sep sep-single sep-solid\" style=\"border-color:#e2e2e2;\"><\/div><\/div><\/div><div class=\"fusion-title title fusion-title-23 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Reference 4.1<\/h4><\/div><div class=\"fusion-text fusion-text-18\"><ol>\n<li><em>Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Rini B et al. Lancet Oncol 2016; 17: 1317\u201324.<\/em><\/li>\n<li><em>DaRenCa guidelines<\/em><\/li>\n<li><em>Freed SZ, Halperin JP, Gordon M. Idiopathic regression of metastases from renal cell carcinoma. The Journal of urology. 977;118(4):538\u201342.<\/em><\/li>\n<li><em>Axel Bex et al. Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma. Eur Urol 2018; 74: 805-809<\/em><\/li>\n<li><em>DaRenCa guidelines, ESMO guideline og Bhindi et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol; 2019: 111-128<\/em><\/li>\n<\/ol>\n<\/div><div class=\"fusion-title title fusion-title-24 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Reference 4.2<\/h4><\/div><div class=\"fusion-text fusion-text-19\"><ol>\n<li><em>Delacroix SE, Wood CG, Jonasch E. Renal neoplasia. In: Taal MW, Chertow GM, Marsden PA, Skorecki K, Yu ASL, et al., eds. Brenner &amp; Rector\u2019s The Kidney. 9th ed. Philadelphia, PA: Elsevier Saunders; 2012:1508\u20131535.<\/em><\/li>\n<li><em>Ljungberg B, Bensalah K, Bex A, et al. EAU guidelines on renal cell carcinoma: 2016 update. European Association of Urology. https:\/\/uroweb.org\/guideline\/renal-cell-carcinoma\/. Accessed June 25, 2016.<\/em><\/li>\n<li><em>Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practise Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 suppl 3:iii49-iii56,<\/em><\/li>\n<li><em>Pili R, Kauffman E, Rodriguez R. Cancer of the kidney. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff\u2019s Clinical Oncology. 5th ed. Philadelphia, PA: Elsevier Churchill Livingstone; 2014:1416-1444.e5. Chapter 82.<\/em><\/li>\n<li><em>Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373: 1119-1132.<\/em><\/li>\n<li><em>Banumathy G, Cairns P. Cancer Biol Ther 2010;10:658\u201364<\/em><\/li>\n<\/ol>\n<\/div><div class=\"fusion-title title fusion-title-25 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Reference 4.3<\/h4><\/div><div class=\"fusion-text fusion-text-20\"><ol>\n<li><em>DaRenCa guidelines<\/em><\/li>\n<li><em>Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMsm registry. Fishman et al. J Immunother Cancer. 2019.)<\/em><\/li>\n<li><em>Current status and future directions of immunotherapy in renal cell carcinoma. Considine B &amp; Hurwithz M. Curr Oncol Rep. 2019.<\/em><\/li>\n<li><em>Cancerimmunterapi, Kjelden JW et al. Ugeskrift for l\u00e6ger. 2018<\/em><\/li>\n<li><em>Tumour Immunotherapy Directed at PD-1. Ribas A. NEJM 2012.)<\/em><\/li>\n<li><em>Immunterapi er kr\u00e6ftbehandling med en helt ny bivirkningsprofil. Kondrup et al. Ugeskrift for l\u00e6ger. 2017.<\/em><\/li>\n<li><em>Ribas A. NEJM 2012<\/em><\/li>\n<\/ol>\n<\/div><div class=\"fusion-title title fusion-title-26 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Reference 4.4<\/h4><\/div><div class=\"fusion-text fusion-text-21\"><ol>\n<li><em>The Danish Cancer Society<\/em><\/li>\n<li><em>DaRenCa guideline<\/em><\/li>\n<li><em>ESMO guidelines<\/em><\/li>\n<\/ol>\n<\/div><div class=\"fusion-title title fusion-title-27 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Reference 4.5<\/h4><\/div><div class=\"fusion-text fusion-text-22\"><ol>\n<li><em>Kidney Cancer: Toxicity Management, Symptom Control,and Palliative Care. Sinibaldi et al. JCO. 2018<\/em><\/li>\n<li><em>The Danish Cancer Society<\/em><\/li>\n<li><em>Symptomkontrol i palliativ medicin 5. udg., Steen Andersen et al, FADL\u2019s forlag, KBH 2012<\/em><\/li>\n<\/ol>\n<\/div><\/div><\/div><\/div><\/div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-6 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-margin-top:4px;--awb-background-color:var(--awb-color3);--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-5 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:1.92%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:1.92%;--awb-width-medium:100%;--awb-order-medium:0;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-title title fusion-title-28 fusion-title-center fusion-title-text fusion-title-size-five\" style=\"--awb-text-color:#c1c1c1;--awb-sep-color:#e2e2e2;\"><div class=\"title-sep-container title-sep-container-left\"><div class=\"title-sep sep-single sep-solid\" style=\"border-color:#e2e2e2;\"><\/div><\/div><span class=\"awb-title-spacer\"><\/span><h5 class=\"fusion-title-heading title-heading-center\" style=\"margin:0;\">Toxicity management<\/h5><span class=\"awb-title-spacer\"><\/span><div class=\"title-sep-container title-sep-container-right\"><div class=\"title-sep sep-single sep-solid\" style=\"border-color:#e2e2e2;\"><\/div><\/div><\/div><div class=\"fusion-title title fusion-title-29 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Reference 5.1<\/h4><\/div><div class=\"fusion-text fusion-text-23\"><ol>\n<li><em>Schmidinger M. EJC Suppl 2013; 11:172\u2013191;<\/em><\/li>\n<\/ol>\n<\/div><div class=\"fusion-title title fusion-title-30 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Reference 5.2.2<\/h4><\/div><div class=\"fusion-text fusion-text-24\"><ol>\n<li><em>Dobbin et al, Heart 2018<\/em><\/li>\n<li><em>Cardiology company\u2019s website<\/em><\/li>\n<\/ol>\n<\/div><div class=\"fusion-title title fusion-title-31 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Reference 5.2.7<\/h4><\/div><div class=\"fusion-text fusion-text-25\"><ol>\n<li><em>Brown R; Targeted therapy 2011 V6<\/em><\/li>\n<li><em>Danish Endocrinology Society\u2019s website<\/em><\/li>\n<\/ol>\n<\/div><div class=\"fusion-title title fusion-title-32 fusion-sep-none fusion-title-text fusion-title-size-four\" style=\"--awb-margin-top:33px;--awb-margin-bottom:33px;\"><h4 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Reference 5.3<\/h4><\/div><div class=\"fusion-text fusion-text-26\"><ol>\n<li><em>Poskow et al, NEJM 2018<\/em><\/li>\n<li><em>Haanen JB et al, ann oncol, 2017;28;IV 119\u2013141<\/em><\/li>\n<li><em>Brahmer JR et, JCO 2018<\/em><\/li>\n<li><em>Nagai et al, Int J Clin Oncol 2018<\/em><\/li>\n<li><em>Immunotherapy is cancer treatment with a completely new adverse reaction profile. Kondrup et al. The Danish medical journal, Ugeskrift for l\u00e6ger. 2017<\/em><\/li>\n<li><em>Management of toxicities from immunotherapy: ESMO Clinical Practise Guidelines for diagnosis, treatment and follow-up.<\/em><\/li>\n<li><em>Management of Immunotherapy-Related Toxicities, Version 1,2019; Thompson JA. J Natl Compr Canc Netw. 2019.)<\/em><\/li>\n<li><em>Champiat et al, Ann Oncol 2016<\/em><\/li>\n<\/ol>\n<\/div><\/div><\/div><\/div><\/div><div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-7 fusion-flex-container has-pattern-background has-mask-background nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:7px;--awb-border-radius-top-right:7px;--awb-border-radius-bottom-right:7px;--awb-border-radius-bottom-left:7px;--awb-overflow:hidden;--awb-margin-top:4px;--awb-background-color:var(--awb-color3);--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:1248px;margin-left: calc(-4% \/ 2 );margin-right: calc(-4% \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-6 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:1.92%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:1.92%;--awb-width-medium:100%;--awb-order-medium:0;--awb-spacing-right-medium:1.92%;--awb-spacing-left-medium:1.92%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-title title fusion-title-33 fusion-title-center fusion-title-text fusion-title-size-five\" style=\"--awb-text-color:#c1c1c1;--awb-margin-top:25px;--awb-sep-color:#e2e2e2;\"><div class=\"title-sep-container title-sep-container-left\"><div class=\"title-sep sep-single sep-solid\" style=\"border-color:#e2e2e2;\"><\/div><\/div><span class=\"awb-title-spacer\"><\/span><h5 class=\"fusion-title-heading title-heading-center\" style=\"margin:0;\">Overview of all chapters<\/h5><span class=\"awb-title-spacer\"><\/span><div class=\"title-sep-container title-sep-container-right\"><div class=\"title-sep sep-single sep-solid\" style=\"border-color:#e2e2e2;\"><\/div><\/div><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-7 fusion_builder_column_1_6 1_6 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:16.666666666667%;--awb-margin-top-large:0px;--awb-spacing-right-large:11.52%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:11.52%;--awb-width-medium:16.666666666667%;--awb-order-medium:0;--awb-spacing-right-medium:11.52%;--awb-spacing-left-medium:11.52%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-8 fusion_builder_column_2_3 2_3 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:66.666666666667%;--awb-margin-top-large:0px;--awb-spacing-right-large:2.88%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:2.88%;--awb-width-medium:66.666666666667%;--awb-order-medium:0;--awb-spacing-right-medium:2.88%;--awb-spacing-left-medium:2.88%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div style=\"text-align:center;\"><a class=\"fusion-button button-flat fusion-button-default-size button-custom fusion-button-default button-1 fusion-button-span-yes fusion-has-button-gradient\" style=\"--button_bevel_color:rgba(89,96,104,0.7);--button_bevel_color_hover:rgba(89,96,104,0.9);--button_accent_color:var(--awb-color6);--button_border_color:#e0e0e0;--button_accent_hover_color:var(--awb-color1);--button_border_hover_color:var(--awb-color3);--button_border_width-top:1px;--button_border_width-right:1px;--button_border_width-bottom:1px;--button_border_width-left:1px;--button_gradient_top_color:rgba(89,96,104,0.07);--button_gradient_bottom_color:rgba(89,96,104,0.33);--button_gradient_top_color_hover:#003c68;--button_gradient_bottom_color_hover:#003c68;--button_padding-top:20px;--button_padding-bottom:20px;--button_margin-top:15px;--button_margin-bottom:3px;\" target=\"_self\" data-hover=\"icon_slide\" href=\"http:\/\/d1s07skqdwll4z.cloudfront.net\/mrcc-tool\/1-introduction-rcc\/\"><span class=\"fusion-button-text\">1. Introduction<\/span><i class=\"fa-angle-right fas button-icon-right\" aria-hidden=\"true\"><\/i><\/a><\/div><div style=\"text-align:center;\"><a class=\"fusion-button button-flat fusion-button-default-size button-custom fusion-button-default button-2 fusion-button-span-yes fusion-has-button-gradient\" style=\"--button_accent_color:var(--awb-color6);--button_border_color:#e0e0e0;--button_accent_hover_color:var(--awb-color1);--button_border_hover_color:var(--awb-color3);--button_border_width-top:1px;--button_border_width-right:1px;--button_border_width-bottom:1px;--button_border_width-left:1px;--button_gradient_top_color:rgba(89,96,104,0.07);--button_gradient_bottom_color:rgba(89,96,104,0.33);--button_gradient_top_color_hover:#003c68;--button_gradient_bottom_color_hover:#003c68;--button_padding-top:20px;--button_padding-bottom:20px;--button_margin-top:3px;--button_margin-bottom:3px;\" target=\"_self\" data-hover=\"icon_slide\" href=\"http:\/\/d1s07skqdwll4z.cloudfront.net\/mrcc-tool\/2-symptoms-and-diagnosis\/\"><span class=\"fusion-button-text\">2. Symptoms and diagnosis<\/span><i class=\"fa-angle-right fas button-icon-right\" aria-hidden=\"true\"><\/i><\/a><\/div><div style=\"text-align:center;\"><a class=\"fusion-button button-flat fusion-button-default-size button-custom fusion-button-default button-3 fusion-button-span-yes fusion-has-button-gradient\" style=\"--button_accent_color:var(--awb-color6);--button_border_color:#e0e0e0;--button_accent_hover_color:var(--awb-color1);--button_border_hover_color:var(--awb-color3);--button_border_width-top:1px;--button_border_width-right:1px;--button_border_width-bottom:1px;--button_border_width-left:1px;--button_gradient_top_color:rgba(89,96,104,0.07);--button_gradient_bottom_color:rgba(89,96,104,0.33);--button_gradient_top_color_hover:#003c68;--button_gradient_bottom_color_hover:#003c68;--button_padding-top:20px;--button_padding-bottom:20px;--button_margin-top:3px;--button_margin-bottom:3px;\" target=\"_self\" data-hover=\"icon_slide\" href=\"http:\/\/d1s07skqdwll4z.cloudfront.net\/mrcc-tool\/3-management-of-mrcc\/\"><span class=\"fusion-button-text\">3. Management of mRCC<\/span><i class=\"fa-angle-right fas button-icon-right\" aria-hidden=\"true\"><\/i><\/a><\/div><div style=\"text-align:center;\"><a class=\"fusion-button button-flat fusion-button-default-size button-custom fusion-button-default button-4 fusion-button-span-yes fusion-has-button-gradient\" style=\"--button_accent_color:var(--awb-color6);--button_border_color:#e0e0e0;--button_accent_hover_color:var(--awb-color1);--button_border_hover_color:var(--awb-color3);--button_border_width-top:1px;--button_border_width-right:1px;--button_border_width-bottom:1px;--button_border_width-left:1px;--button_gradient_top_color:rgba(89,96,104,0.07);--button_gradient_bottom_color:rgba(89,96,104,0.33);--button_gradient_top_color_hover:#003c68;--button_gradient_bottom_color_hover:#003c68;--button_padding-top:20px;--button_padding-bottom:20px;--button_margin-top:3px;--button_margin-bottom:3px;\" target=\"_self\" data-hover=\"icon_slide\" href=\"http:\/\/d1s07skqdwll4z.cloudfront.net\/mrcc-tool\/4-treatment\/\"><span class=\"fusion-button-text\">4. Treatment<\/span><i class=\"fa-angle-right fas button-icon-right\" aria-hidden=\"true\"><\/i><\/a><\/div><div style=\"text-align:center;\"><a class=\"fusion-button button-flat fusion-button-default-size button-custom fusion-button-default button-5 fusion-button-span-yes fusion-has-button-gradient\" style=\"--button_accent_color:var(--awb-color6);--button_border_color:#e0e0e0;--button_accent_hover_color:var(--awb-color1);--button_border_hover_color:var(--awb-color3);--button_border_width-top:1px;--button_border_width-right:1px;--button_border_width-bottom:1px;--button_border_width-left:1px;--button_gradient_top_color:rgba(89,96,104,0.07);--button_gradient_bottom_color:rgba(89,96,104,0.33);--button_gradient_top_color_hover:#003c68;--button_gradient_bottom_color_hover:#003c68;--button_padding-top:20px;--button_padding-bottom:20px;--button_margin-top:3px;--button_margin-bottom:3px;\" target=\"_self\" data-hover=\"icon_slide\" href=\"http:\/\/d1s07skqdwll4z.cloudfront.net\/mrcc-tool\/5-toxicity-management\/\"><span class=\"fusion-button-text\">5. Toxicity management<\/span><i class=\"fa-angle-right fas button-icon-right\" aria-hidden=\"true\"><\/i><\/a><\/div><div style=\"text-align:center;\"><a class=\"fusion-button button-flat fusion-button-default-size button-custom fusion-button-default button-6 fusion-button-span-yes fusion-has-button-gradient\" style=\"--button_accent_color:var(--awb-color6);--button_border_color:#e0e0e0;--button_accent_hover_color:var(--awb-color1);--button_border_hover_color:var(--awb-color3);--button_border_width-top:1px;--button_border_width-right:1px;--button_border_width-bottom:1px;--button_border_width-left:1px;--button_gradient_top_color:rgba(89,96,104,0.07);--button_gradient_bottom_color:rgba(89,96,104,0.33);--button_gradient_top_color_hover:#003c68;--button_gradient_bottom_color_hover:#003c68;--button_padding-top:20px;--button_padding-bottom:20px;--button_margin-top:3px;--button_margin-bottom:3px;\" target=\"_self\" data-hover=\"icon_slide\" href=\"http:\/\/d1s07skqdwll4z.cloudfront.net\/frequently-asked-questions-faqs\/\"><span class=\"fusion-button-text\">6. Frequently asked questions (FAQs)<\/span><i class=\"fa-angle-right fas button-icon-right\" aria-hidden=\"true\"><\/i><\/a><\/div><\/div><\/div><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-9 fusion_builder_column_1_6 1_6 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:16.666666666667%;--awb-margin-top-large:0px;--awb-spacing-right-large:11.52%;--awb-margin-bottom-large:20px;--awb-spacing-left-large:11.52%;--awb-width-medium:16.666666666667%;--awb-order-medium:0;--awb-spacing-right-medium:11.52%;--awb-spacing-left-medium:11.52%;--awb-width-small:100%;--awb-order-small:0;--awb-spacing-right-small:1.92%;--awb-spacing-left-small:1.92%;\"><div class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"><\/div><\/div><\/div><\/div>\n<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":7457,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"100-width.php","meta":{"footnotes":""},"class_list":["post-7633","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/no\/wp-json\/wp\/v2\/pages\/7633","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/no\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/no\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/no\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/no\/wp-json\/wp\/v2\/comments?post=7633"}],"version-history":[{"count":4,"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/no\/wp-json\/wp\/v2\/pages\/7633\/revisions"}],"predecessor-version":[{"id":11012,"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/no\/wp-json\/wp\/v2\/pages\/7633\/revisions\/11012"}],"up":[{"embeddable":true,"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/no\/wp-json\/wp\/v2\/pages\/7457"}],"wp:attachment":[{"href":"https:\/\/d1s07skqdwll4z.cloudfront.net\/no\/wp-json\/wp\/v2\/media?parent=7633"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}